Elazer R. Edelman
Independent DirectorDr. Elazer R. Edelman, FACC, M.D., Ph.D., was Member of Advisory Board of Form Bio, Inc. Dr. Edelman serves as a Member of Scientific Advisory Board at Expansion Technologies, Inc. Dr. Edelman serves as Chairman of the medical advisory board of Peregrine Ventures from 2024. He serves as Member of Scientific Advisory Board at Colossal Biosciences Inc. He serves as Member of Advisory Board at Form Bio Inc. He serves as Member of Advisory Board at Dyad Medical Inc. He serves as Independent Director at Butterfly Network, Inc. since March 10, 2021. He is Member of Medical and Scientific Advisory Board at Tesseract Health, Inc. He has been a Founding Scientific Adviser at Xenter, Inc. and is its Chair of Scientific Advisory Board and is its Director since May 2021. He serves as Scientific Founder, Scientific Consultant Advisor and Director of Alxerion Biotech Corporation. He served as a Member of the Scientific Advisory Board at Alucent Biomedical, Inc. He serves as an Advisor at New Technology Ventures. He serves as a Member of the Advisory Board at Amide Technologies, Inc. He also serves as a Scientific Advisor of Ascent Biomedical Ventures. Dr. Edelman has pioneered basic findings in both vascular biology and the development and assessment of biotechnology including research on antisense oligonucleotides, HDL receptor biology and tissue-engineered endothelial implants. Dr. Edelman also serves as a Senior Advisor at PureTech Ventures. He co-founded Pervasis Therapeutics, Inc. in 2003 and serves as its Advisor. Dr. Edelman served as Scientific Advisor of BioCardia, Inc. He was an Advisor at Highland Capital Partners. Dr. Edelman focused on medical technology and in this capacity, he worked with the healthcare team to identify and evaluate new opportunities at the cutting edge of science and medicine. He served as a Member of the Advisory Board of Catalyst Health Ventures and serves as a Member of the Scientific Advisory Board of Exogenesis Corporation and Mi3 Venture Partners. He served as Member of the Scientific Advisory Board of Lyra Therapeutics, Inc. (formerly known as 480 Biomedical, Inc.). He served as Director of Pervasis Therapeutics, Inc. Dr. Edelman serves as a Member of the Scientific Advisory Board at Conor Medsystems, LLC and AngioScore, Inc. He has been a Member of the Scientific Advisory Board of FluoroPharma Medical, Inc. since July 31, 2007. He serves as a Member of the Advisory Board at InspireMD, Inc. He serves as Director of the Harvard-MIT Biomedical Engineering Center (BMEC) and runs the Edelman Laboratory. He serves as a Member of the Advisory Board of Percardia, Inc. He served as a Member of the Scientific Advisory Board at Neovasc Inc. He served as a Director of Elutex Ltd. He serves as Scientific Co-Founder at PanTher Therapeutics, LLC since 2014 and served as its Director since 2014. Dr. Edelman is the Founder and Member of the Board of Directors of Autus Valve Technologies and Inc since 2019 and BioDevek, Inc since 2015. He served as Director of Echo Therapeutics, Inc. from December 28, 2015, to September 26, 2016. He served as a Member of the Scientific Advisory Board at Gelesis, Inc. He served as a Member of the Scientific Advisory Board at IntelliDx, Inc. Dr. Edelman's clinical and medical training and interests, focusing on understanding how tissue architecture and biochemical regulation contribute to local growth control. Many of his findings are in clinical trial validation. He is a Professor of Medicine at Harvard Medical School. Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT and a Coronary Care Unit Cardiologist and an Associate Physician at the Brigham and Women's Hospital in Boston. He is the winner of numerous awards and honors and is the author of numerous major publications, patents and reports. From 1984 to 1989, Dr. Edelman held three clinical and research fellowships in Internal Medicine, Cardiovascular Medicine and Pathology at Harvard Medical School. He performed his graduate work on regulated and controlled drug delivery systems at MIT. He is the Director of the Institute of Medical Engineering and Science (the Edelman Lab) at the Massachusetts Institute of Technology where he is also Director of the Clinical Research Center and the current occupant of the Edward J. Poitras Chair as Professor of Medical Engineering and Science at the Massachusetts Institute of Technology which he joined in 1993, Professor of Medicine at Harvard Medical School which he joined in 1989 and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital in Boston which he has been associated since 1984. His research melds clinical and medical training, focusing on how tissue architecture and local biochemical, biomechanical and flow dynamic regulation maintain homeostasis. He and his students have used fluid and hemodynamics to guide basic scientific investigation of vascular signaling and repair on multiple scales and dimensions and in the applied realm to guide the development of critical clinical devices from endovascular implants to mechanical cardiovascular support devices. His clinical work utilizes these findings to care for people critically ill with instabilities inflow and perfusion. Dr. Edelman is a fellow of the American College of Cardiology, American Heart Association, American Institute for Medical and Biological Engineering, American Society for Clinical Investigation, American Academy of Arts and Sciences, National Academy of Medicine, National Academy of Engineering and National Academy of Inventors. Dr. Edelman is a Fellow and has also earned a diploma from the American College of Cardiology and the American Heart Association. He received a Ph.D. in Medical Engineering and Medical Physics from MIT in 1984, an M.Sc. in Electrical Engineering and Computer Sciences from MIT in 1979, an M.D. in Medicine from the Harvard Medical School in 1983 and a B.Sc. in Bioelectrical Engineering and Applied Biology from MIT in 1978.
Positions
- Company NameButterfly Network, Inc.Stock CodeBFLYPositionIndependent DirectorColleagues
- JMJoseph M. DeVivoCEO, President & Chairman of the Board
- JMJonathan M. RothbergFounder & Director
- JNJohn N. DohertyExecutive VP & CFO
- SCSteven CashmanExecutive VP & Chief Business Officer
- MCMegan CarlsonChief Accounting Officer & Senior VP of Finance & Accounting
- LMLawrence Michael RobbinsLead Independent Director
- SLS. Louise PhanstielIndependent Director
- Company NameLyra Therapeutics, Inc.Stock CodeLYRAPositionVP of Finance & RiskColleagues
- CSCarmichael S. RobertsCo-Founder
- CAC. Ann MerrifieldIndependent Director
- VBVineeta BelangerSenior Vice President of Clinical Affairs
- ANAllison NanceSenior Vice President of Regulatory Affairs
- ERElazer R. EdelmanVP of Finance & Risk
- WBW. Bradford SmithIndependent Director
- JRJames R. TobinLead Independent Director
- NLNancy L. SnydermanIndependent Director
